Build status - In Progress

Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )
Recruiting
99 years or below
All
Phase 3
6 participants needed
1 Location

Brief description of study

This is a study to find out whether patients with active forms of Relapsing Multiple Sclerosis (RMS) who are treated with dimethyl fumarate (Tecfidera®) can be treated better by the addition of ponesimod (study drug). The purpose is also to evaluate the effect on disability and the safety of these two drugs together in comparison to Tecfidera® alone (plus placebo).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: ['Breast Cancer', 'Hereditary Breast/Ovarian Cancer (brca1, brca2)', 'Heart Diseases', 'Drug-Induced Cardiomyopathy']
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 828873

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center